VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY
Ramir Luan Perin, Aderson Omar Mourão Cintra Damião, Cristina Flores, Juliano Coelho Ludvig, Daniéla Oliveira Magro, Eron Fábio Miranda, Antonio Carlos de Moraes, Rodrigo Bremer Nones, Fábio Vieira Teixeira, Marco Zeroncio, Paulo Gustavo Kotze, Ramir Luan Perin, Aderson Omar Mourão Cintra Damião, Cristina Flores, Juliano Coelho Ludvig, Daniéla Oliveira Magro, Eron Fábio Miranda, Antonio Carlos de Moraes, Rodrigo Bremer Nones, Fábio Vieira Teixeira, Marco Zeroncio, Paulo Gustavo Kotze
Abstract
Background: There is scarce data regarding efficacy and safety of vedolizumab in inflammatory bowel diseases in Latin America.
Objective: To describe the first observational real-world experience with vedolizumab in Latin American inflammatory bowel diseases patients.
Methods: Retrospective observational multicentric study of patients with Crohn's disease (CD) and ulcerative colitis (UC) who used vedolizumab at any phase of their treatment. Clinical remission and response (according to Harvey-Bradshaw index for CD and Mayo score for UC), mucosal healing, need for surgery and adverse events were evaluated.
Results: A total of 90 patients were included (52 with CD and 38 with UC), the majority with previous exposure to anti-TNF agents (88.46% in CD and 76.31% in UC). In CD (as observed analysis) remission rates at weeks 12, 26 and 52 were 42.89% (21/49), 61.9% (26/42) and 46.15% (12/26), respectively. In UC, remission rates at weeks 12, 26 and 52 were 28.94% (11/38), 36.66% (11/30) and 41.17% (7/17). Mucosal healing rates were 36.11% in CD and 43.4% in UC. During the study period, 7/52 CD patients underwent major abdominal surgery and 4/38 UC patients needed colectomy.
Conclusion: Vedolizumab was effective in induction and maintenance of clinical response and remission in CD and UC, with no new safety signs.
Source: PubMed